Zydus gets USFDA nod for Bosentan oral suspension tablets

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹912.50

prior close

₹919.75

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-1.5%+0.3% vs market

Pharmaceuticals peers, median of 157sector-1.2%-0.1% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty 100 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-0.7

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-1.5+0.3-1.2-0.1

Next day

-1.2-1.0-0.1-1.4+0.3

-0.8-0.5-0.3-1.6+0.9

-0.6-1.4+0.8-2.1+1.5

+0.7-1.1+1.8-2.4+3.1

+2.8-1.0+3.8-2.0+4.8

-0.8-3.5+2.7-4.6+3.8

15d

-0.9-10.0+9.0-6.8+5.9

-3.7-10.7+7.0-7.5+3.8

+2.5-4.7+7.1+0.5+1.9

+11.5-7.4+18.9+3.2+8.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences received final USFDA approval for Bosentan tablets for oral suspension, 32 mg, used to treat Pulmonary Arterial Hypertension in children aged 3 and above. The product targets a US market with annual sales of USD 9.3 million (IQVIA MAT Dec 2025). It will be made at the group's SEZ Ahmedabad facility. Zydus now has 432 approvals and 505 ANDA filings since FY 2003-04.

Likely market impact

Positive: adds a new generic product to US portfolio in a USD 9.3 million market, strengthening US revenue pipeline.